| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
|
Medicine details |
|
| Medicine name | bivalirudin (Angiox®) |
| Formulation | 250 mg powder for concentrate for solution for injection/infusion |
| Reference number | 615 |
| Indication | Treatment of patients with ST-segment myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) |
| Company | The Medicines Company |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/02/2010 |
| NICE guidance | TA230: Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |